Stuttering is a speech disorder that affects millions of people worldwide, causing disruptions in the flow of speech. For those who stutter, communicating can be a significant challenge, often leading ...

Stuttering is a common speech disorder that can significantly impact an individual’s ability to communicate effectively. While it can be a challenging condition to manage, there are effective ...

Stuttering affects about 1% of the world's population, or millions of people. In fact, famous stars like Julia Roberts and Marilyn Monroe began speaking by stumbling over words. However, this speech ...

Nervousness. Stress. Shyness. Speaking more than one language. Thinking too quickly. None of these are reasons why people stutter. Yet, these misconceptions remain all too prevalent, says Angela ...

Democratic presidential nominee Joe Biden has been outspoken about his stutter and last night at the Democratic National Convention, a young boy with a stutter shared a story about how Biden had ...

Today is Inauguration Day, which got us thinking about speech-making and speeches. President-elect Joe Biden has spoken publicly about his childhood experiences with stuttering and annotating his ...

President Joe Biden, Ed Sheeran and more have talked about their experiences struggling with — and surmounting — a stutter. Read their personal stories Some of the most influential people in the world ...

Even though stuttering in bilinguals has a relatively long research history, there are still many questions that cause debate: Do bilinguals stutter in just one language or in all of their languages?

SAN FRANCISCO (KGO) -- It's estimated that more than 79 million people worldwide live with a stutter. In the Bay Area, there's a small but mighty group looking to spread awareness and acceptance of ...

Gerald Maguire has stuttered since childhood, but you might not guess it from talking to him. For the past 25 years, Maguire — a psychiatrist at the University of California, Riverside — has been ...

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the ...